[HTML][HTML] Phase II trial demonstrates the efficacy and safety of individualized, dosimetry-based 177Lu-DOTATATE treatment of NET patients
A Sundlöv, KS Gleisner, J Tennvall… - European journal of …, 2022 - Springer
Abstract Purpose Radionuclide therapy with 177Lu-DOTATATE is well established for
patients with advanced somatostatin receptor–positive neuroendocrine tumors with a …
patients with advanced somatostatin receptor–positive neuroendocrine tumors with a …
[HTML][HTML] Clinical results of radionuclide therapy of neuroendocrine tumours with 90Y-DOTATATE and tandem 90Y/177Lu-DOTATATE: which is a better therapy …
J Kunikowska, L Królicki… - European journal of …, 2011 - Springer
Purpose Peptide receptor radionuclide therapy (PRRT) using radiolabelled somatostatin
analogues is a treatment option for patients with disseminated neuroendocrine tumours …
analogues is a treatment option for patients with disseminated neuroendocrine tumours …
[HTML][HTML] Prospective observational study of 177Lu-DOTA-octreotate therapy in 200 patients with advanced metastasized neuroendocrine tumours (NETs): feasibility …
U Garske-Román, M Sandström, K Fröss Baron… - European journal of …, 2018 - Springer
Purpose Peptide receptor radionuclide therapy in patients with neuroendocrine tumours has
yielded promising results. This prospective study investigated the feasibility of dosimetry of …
yielded promising results. This prospective study investigated the feasibility of dosimetry of …
Peptide receptor radionuclide therapy with 177Lu-DOTATATE for patients with somatostatin receptor–expressing neuroendocrine tumors: the first US phase 2 …
ES Delpassand, A Samarghandi, S Zamanian… - Pancreas, 2014 - journals.lww.com
Objective Peptide receptor radionuclide therapy with radiolabeled somatostatin analogs is a
novel method of treatment in patients with metastatic neuroendocrine tumors (NETs). For the …
novel method of treatment in patients with metastatic neuroendocrine tumors (NETs). For the …
[HTML][HTML] Tandem peptide receptor radionuclide therapy using 90Y/177Lu-DOTATATE for neuroendocrine tumors efficacy and side-effects - polish multicenter …
J Kunikowska, A Zemczak, M Kołodziej, P Gut… - European Journal of …, 2020 - Springer
Introduction One of the concepts of theranostics in nuclear medicine is peptide receptor
radionuclide therapy (PRRT), whereby labeled somatostatin analogs are used for imaging …
radionuclide therapy (PRRT), whereby labeled somatostatin analogs are used for imaging …
Therapy With 177Lu-DOTATATE: Clinical Implementation and Impact on Care of Patients With Neuroendocrine Tumors
AT Kendi, TR Halfdanarson, A Packard… - American Journal of …, 2019 - Am Roentgen Ray Soc
OBJECTIVE. The purpose of this article is to enhance knowledge of the clinical
implementation of peptide receptor radionuclide therapy (PRRT) and its impact on care of …
implementation of peptide receptor radionuclide therapy (PRRT) and its impact on care of …
Minor changes in effective half-life during fractionated 177Lu-Octreotate therapy
U Garske, M Sandström, S Johansson, A Sundin… - Acta …, 2012 - Taylor & Francis
Abstract Aims. Fractionated 177Lu-DOTA-octreotate therapy has been reported to be an
effective treatment option for patients with generalized neuroendocrine tumors. In our clinic …
effective treatment option for patients with generalized neuroendocrine tumors. In our clinic …
[HTML][HTML] Individualised 177Lu-DOTATATE treatment of neuroendocrine tumours based on kidney dosimetry
A Sundlöv, K Sjögreen-Gleisner, J Svensson… - European journal of …, 2017 - Springer
Purpose To present data from an interim analysis of a Phase II trial designed to determine
the feasibility, safety, and efficacy of individualising treatment based on renal dosimetry, by …
the feasibility, safety, and efficacy of individualising treatment based on renal dosimetry, by …
Safety of multiple repeated cycles of 177Lu-octreotate in patients with recurrent neuroendocrine tumour
A Yordanova, K Mayer, P Brossart… - European journal of …, 2017 - Springer
Purpose Peptide receptor radionuclide therapy (PRRT) is an effective therapy in patients
with a somatostatin receptor-positive neuroendocrine tumour (NET). Still unclear is how …
with a somatostatin receptor-positive neuroendocrine tumour (NET). Still unclear is how …
177Lu‐[DOTA0,Tyr3] octreotate therapy in patients with disseminated neuroendocrine tumors: Analysis of dosimetry with impact on future therapeutic strategy
M Garkavij, M Nickel, K Sjögreen‐Gleisner… - Cancer, 2010 - Wiley Online Library
Abstract BACKGROUND: 177Lu‐(DOTA0, Tyr3) octreotate is a new treatment modality for
disseminated neuroendocrine tumors. According to a consensus protocol, the calculated …
disseminated neuroendocrine tumors. According to a consensus protocol, the calculated …
相关搜索
- somatostatin receptor 177lu dotatate
- neuroendocrine tumors 177lu dotatate
- net patients 177lu dotatate
- net patients efficacy and safety
- efficacy and safety 177lu dotatate
- lu dotatate kidney dosimetry
- lu dotatate radionuclide therapy
- clinical implementation 177lu dotatate
- lu dotatate side effects
- impact on care 177lu dotatate
- lu dotatate multicenter experience
- lu dotatate neuroendocrine tumours
- lu dotatate therapy option